Category: Medicine

High-dose vitamin B3 may enhance immune function and slow the progression of glioblastoma, with 82% of trial patients showing no disease progression after six months, according to a recent study.

High-dose vitamin B3, commonly known as niacin, may significantly boost immune function and improve short-term disease control in patients with glioblastoma when used alongside standard therapies, according to early preclinical studies.

Glioblastoma is a highly aggressive and fast-growing brain cancer that originates from cells in the brain and spinal cord. Previous laboratory experiments conducted on mice indicated that niacin could extend survival rates. Researchers at the University of Calgary sought to determine whether these benefits could also be observed in humans.

The clinical trial included 24 patients diagnosed with glioblastoma, a condition that typically has a median survival rate of approximately 12 to 18 months. Remarkably, six months after receiving niacin in conjunction with standard treatments—surgery, radiation, and chemotherapy—82% of the patients exhibited no disease progression. This is a notable increase compared to the typical 54% of patients who experience no progression under standard treatment alone, as reported in the study’s press release.

Additionally, niacin was found to restore functionality in weakened immune cells, enhancing their ability to target and eliminate tumor cells. The findings, which highlight a 28% improvement in disease progression, were published in the Journal of Neuro-Oncology.

“Normally, the immune system attempts to counter and prevent tumor growth; however, glioblastoma actively suppresses the immune response,” said Dr. Wee Yong, PhD, a neuroscientist involved in the study. “Niacin treatment rejuvenates immune cells so they can perform their essential functions: attacking and destroying cancer cells. I view this as an ongoing ‘battle for the brain.’”

Looking ahead, the research team plans to enroll an additional 24 patients by the end of 2026 or early 2027 for the next phase of the trial, which will focus on assessing niacin’s safety and its effects on immune system activation.

Dr. Marc Siegel, a senior medical analyst at Fox News, noted that previous studies have demonstrated that vitamin B3 can reduce inflammation and enhance immune function. “Vitamins, including the B vitamins—especially niacin—are often underrecognized as immune boosters,” he stated, although he was not involved in the study.

Despite these promising early results, the researchers have urged caution regarding the implications of their findings. “Glioblastoma is the most aggressive brain cancer in adults, and patient survival rates have not significantly improved in the past two decades,” said lead study author Roldan Urgoiti, a clinical associate professor at the CSM. “While any potential treatment that may help should be explored, it requires strict protocols and safety monitoring.”

The study’s limitations include its small sample size, short follow-up period, and the absence of a randomized control group. The researchers emphasized the need for larger, controlled trials to verify their findings.

Furthermore, the researchers cautioned that high doses of vitamins can pose health risks, and any supplementation should be closely monitored by healthcare professionals. Dr. Siegel also acknowledged that niacin can have side effects, such as skin flushing. “While there may be a small impact here, this information is useful, though it is clearly not a cure,” he added.

As the research progresses, the scientific community remains hopeful that niacin could play a role in enhancing treatment options for glioblastoma patients, but further investigation is essential to fully understand its potential benefits and risks.

According to Fox News, the ongoing exploration of vitamin therapies in cancer treatment represents a promising avenue for improving patient outcomes in the face of challenging diagnoses.

Clinical trials are essential to medical advancements, yet misconceptions and lack of awareness hinder participation, impacting the development of new treatments and therapies.

Clinical trials serve as the cornerstone of medical advancements, leading to breakthroughs in cancer treatments, vaccines, and diagnostic tools. However, many people remain unaware of their significance until faced with a serious health diagnosis. This gap in knowledge, combined with prevalent misconceptions, can have serious consequences. It can slow the progress of promising treatments, prevent patients from accessing cutting-edge care, and limit the applicability of trial results due to a lack of diverse participants.

One of the most common misconceptions surrounding clinical trials is that they are only for patients with severe illnesses, leading to the belief that medical professionals recommend trials only when there is little hope left. Additionally, the fear of being treated as a “guinea pig” is a widespread concern that transcends various patient populations, regardless of their previous research experiences. Many potential participants worry that they might receive a placebo, rendering their involvement ineffective.

According to the clinical center at the National Institutes of Health (NIH), only about 1% of the U.S. population participates in clinical trials. Paradoxically, nearly 80% of the general public holds a positive view of clinical research, despite these fears and misconceptions. Professor Lisa Goldman Rosas, an expert in Epidemiology and Population Health at Stanford’s School of Medicine, notes, “Community mistrust and lack of awareness are major barriers to participation in clinical trials, particularly in underrepresented communities. History plays a big role, and we have to work hard to educate the community and gain people’s trust.”

So, what exactly is a clinical trial? Clinical trials are meticulously designed research studies aimed at testing new medical interventions—such as drugs, devices, procedures, or preventive measures—to assess their safety and effectiveness before they become widely available. These trials are crucial for advancing medical research and developing new treatments. Every prescribed medication in the U.S. has undergone this rigorous testing process, which can take a decade or longer before receiving approval from the Food and Drug Administration (FDA).

In clinical trials, human subjects are assigned to one or more interventions, which may include a placebo or other control, to evaluate the effects on health-related biomedical or behavioral outcomes. Each study follows a predefined, reviewed, and approved process outlined in a written protocol, detailing how subjects will be assigned to different groups or “arms” of the trial.

A fundamental principle in clinical trial design is that the welfare of participants must always take precedence over the interests of science and society. Ethical considerations are paramount, and all trial protocols undergo ethical review and oversight by independent Institutional Review Boards, as mandated by federal law for all clinical research involving human subjects in the U.S. and many other countries.

There are various types of clinical trials. Approximately 25% are observational, where researchers monitor and record data without intervening. The landmark Framingham Heart Study, which began in 1948, is a prime example, tracking over 5,000 residents of Framingham, Massachusetts, to identify major cardiovascular disease risk factors. The remaining 75% of trials test medical interventions, with about 40% focused on drugs, medications, or vaccines, and 10% on medical devices such as implants and surgical instruments.

Drug development typically involves several phases, each with distinct objectives. The initial phase tests safety and dosage in small groups to explore optimal dosing and short-term toxicity. If a safe dose range is identified, the trial progresses to Phase II, which evaluates effectiveness and side effects in larger groups, typically composed of subjects with the condition being addressed. This phase must demonstrate that the treatment yields clinically meaningful results to justify further investment in the trials.

Phase III trials compare the new treatment to a placebo, current standard care, or other treatment modalities in large populations. These high-stakes trials account for 50-70% of total clinical development costs, and only about one in three drugs advances to this phase. What appears promising in earlier testing may not translate to clinical benefit.

Once Phase III is completed and regulatory approval is obtained, Phase IV trials monitor the real-world use of the new drug, device, or intervention, utilizing observational data from medical records, registries, or adverse-event databases.

The role of volunteers in clinical trials is vital. Trials investigating interventions for specific conditions need to enroll patients with those conditions, while prevention trials may involve individuals at risk for those conditions. By assembling a representative group of volunteers, researchers can ensure that the results are applicable to the broader community.

Healthy volunteers also play a crucial role in clinical research. For most new medications, excluding those for cancer and certain toxic biologics, healthy individuals can participate in Phase I trials to establish safety profiles, determine appropriate dosing ranges, and study how drugs are absorbed and metabolized in the body. Their contributions provide essential baseline data that helps researchers distinguish drug effects from disease symptoms in patient populations.

Nearly 60% of healthy volunteers cite societal benefits as their primary motivation for participation, recognizing that their involvement accelerates medical advancements that will ultimately benefit future patients, including their loved ones. By volunteering before facing health challenges themselves, these individuals help establish safety standards that protect all future clinical trial participants and expedite the delivery of promising treatments to those in need.

Clinical trials should be viewed as a social good, essential to enhancing health, extending life, and alleviating the burdens of illness and disability. Increased knowledge and awareness of clinical trials can help individuals understand the true benefits and risks, make informed decisions about participation, and advocate for clinical research within their communities.

As Dr. Francis Collins, a distinguished physician-geneticist and former Director of the NIH, stated, “Signing up for a clinical trial may benefit medical research and help future generations. But it is not strictly an altruistic endeavor. In many instances, trial participants do gain personal advantages, such as improved disease outcomes or better health.”

Understanding clinical trials is crucial for fostering participation and advancing medical research that can lead to innovative treatments and improved health outcomes for all.

Deepanwita Dasgupta, diagnosed with subacute sclerosing panencephalitis after contracting measles at age five, highlights the severe long-term risks associated with the virus.

Deepanwita Dasgupta’s journey began when she was just five years old, playing at her home in Bangalore, India. Her parents noticed that she was stumbling more often, attributing the extra bumps and bruises to her active nature. They thought perhaps her shoes were ill-fitting.

Described by relatives as smart, affectionate, and occasionally mischievous, Deepanwita had a knack for technology, managing to find her favorite show, *Blippi*, on a phone before she even learned the alphabet. She was known for sneaking butter from the fridge for a quick taste.

However, her playful childhood took a drastic turn when her limbs began to jerk uncontrollably. A spinal tap revealed the presence of the measles virus in her cerebrospinal fluid. The virus, contracted during her infancy, had silently made its way to her brain. Now, at eight years old, Deepanwita is paralyzed and unable to speak.

Measles is notorious for causing a range of complications, from diarrhea to death, affecting approximately three in ten infected individuals, according to the Infectious Diseases Society of America. While some complications arise immediately, others may take weeks or even months to manifest. Deepanwita’s condition, known as subacute sclerosing panencephalitis (SSPE), typically takes years to develop.

“People think, ‘Oh, you know, if we get measles, then we’ll be fine, because I know my neighbor had it and they’re fine,’” said Yasmin Khakoo, a leading neurologist in New York City. Khakoo emphasized the dangers of measles, noting that a seven-year-old in South Carolina had to relearn how to walk due to brain swelling, another immediate complication of the virus. In some cases, measles can plant a ticking time bomb in the nervous system, allowing individuals to appear healthy for years before severe problems arise. While some patients may experience temporary disabilities, the condition is almost always fatal.

Before the widespread availability of effective vaccines, SSPE was a common complication in the U.S. In the 1960s, a doctor established a national registry for SSPE patients. Current estimates suggest that about one in 10,000 individuals who contract measles will develop SSPE, with the risk significantly elevated for those infected before the age of five. Countries where measles is endemic, such as India, continue to see regular cases.

As vaccination rates decline and measles outbreaks increase in the U.S., medical professionals are concerned that cases of SSPE will also rise. Since the beginning of 2025, the Centers for Disease Control and Prevention has reported over 3,500 measles cases, surpassing the total from the previous decade, predominantly among unvaccinated individuals, many of whom are children. Last year, a six-year-old in Connecticut was diagnosed with SSPE, and a school-aged child in California died from the condition after contracting measles as an infant.

“We are likely to see SSPE cases going forward, especially if we don’t get this under control,” warned Adam Ratner, a member of the American Academy of Pediatrics’ Committee on Infectious Diseases.

In response to growing concern, the Child Neurology Society published a video in January to educate U.S. clinicians about SSPE, and physicians who have encountered such cases are urging their colleagues to be vigilant.

“We don’t have a way of knowing who’s going to get it, and we don’t have a way of very effectively treating it,” said Aaron Nelson, a professor of neurology at New York University. “The one best thing that we can do, ideally, is to prevent children from having to go through it in the first place.”

The recommended two-dose measles vaccine significantly reduces the risk of contracting the virus, lowering it from 90% to just 3%, thereby decreasing the likelihood of developing SSPE. While the vaccine carries minor risks, such as febrile seizures and a bleeding condition, the risks associated with measles itself are far greater.

Deepanwita’s story is a poignant reminder of the potential consequences of measles. In 2022, she celebrated her fifth birthday, unaware that her health would soon take a tragic turn. At her eighth birthday gathering, Deepanwita, dressed in a pink eyelet dress and supported by a nasal tube, could only blink and move her eyes as she sat before two cakes she could not eat.

Roberto Cattaneo, a molecular biologist at the Mayo Clinic, has been studying SSPE for years. He recently utilized postmortem brain tissue to investigate how the measles virus spreads within the brain. Despite his research, he acknowledges that the exact mechanisms of the virus during the dormant period between initial infection and the onset of neurological symptoms remain largely unknown.

“The problem could be solved with vaccination,” Cattaneo stated, expressing frustration that such a preventable condition still exists. “The U.S. should have no cases of SSPE. It’s just painful.”

As the number of measles outbreaks rises globally, the situation remains dire, particularly in countries like India. In New Delhi, Sheffali Gulati, a pediatric neurologist, sees about ten new SSPE patients each year, referring to the condition as a “delayed echo” of measles outbreaks. The youngest patient she has treated was just three years old.

With families like Deepanwita’s facing the harsh realities of SSPE, the urgent need for vaccination and awareness has never been clearer. The long-term effects of measles can be devastating, and the medical community continues to advocate for prevention to protect future generations.

According to KFF Health News, the importance of vaccination cannot be overstated in the fight against measles and its severe complications.

Vitamin D supplements may reduce the risk of long COVID symptoms, such as fatigue and brain fog, according to a recent study conducted by researchers at Mass General Brigham.

A new study suggests that vitamin D supplements could play a role in alleviating long COVID symptoms, which persist after the initial infection. Researchers at Mass General Brigham investigated whether high doses of vitamin D could affect COVID-19 outcomes, particularly the risk of developing long COVID, a condition characterized by lingering symptoms such as fatigue, shortness of breath, and brain fog. The findings were published in The Journal of Nutrition.

The randomized clinical trial involved 1,747 adults who had recently tested positive for COVID-19, along with 277 members of their households. Participants were assigned to receive either vitamin D3 supplements or a placebo for a duration of four weeks.

Dr. JoAnn Manson, the senior author of the study and a physician at Mass General Brigham, highlighted the potential benefits of vitamin D supplementation for long-term symptoms. “A key takeaway is that vitamin D supplementation looks promising for reducing the risk of developing long COVID but does not appear to affect the severity of the acute infection,” Manson stated.

While the study found that vitamin D supplementation did not significantly alter short-term outcomes, such as symptom severity or the need for hospital visits, a closer examination of participants who adhered to the supplement regimen revealed a noteworthy difference in lingering symptoms. Approximately 21% of those who took vitamin D reported at least one ongoing symptom eight weeks after infection, compared to 25% of participants who received a placebo.

“There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” Manson remarked in a press release. “While we didn’t find that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” she added.

Manson explained that vitamin D may influence longer-term complications due to its role in regulating inflammation within the body. However, the researchers acknowledged several limitations in the trial. The study had to be conducted remotely during the pandemic, and participants began taking vitamin D several days after their COVID diagnosis.

Ideally, Manson noted, supplementation should commence before infection or immediately following diagnosis. She emphasized the need for larger studies to confirm whether vitamin D could effectively reduce the risk or severity of long COVID symptoms.

Researchers are planning additional trials to further explore the potential of vitamin D supplementation in treating individuals already experiencing long COVID.

These findings provide a promising avenue for future research and may offer hope for those grappling with the long-term effects of COVID-19, according to Fox News.

A groundbreaking blood test could identify dementia risk in women up to 25 years before symptoms appear, according to research from the University of California San Diego.

Researchers from the University of California San Diego have developed a blood test that may determine a woman’s risk of developing dementia as early as 25 years before any symptoms manifest. This promising finding centers on a specific biomarker protein associated with the early pathological processes of Alzheimer’s disease, known as phosphorylated tau 217 (p-tau217).

The study analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, conducted in the late 1990s. The participants, aged between 65 and 79, exhibited no signs of cognitive decline at the study’s outset. Over a follow-up period of up to 25 years, researchers found a strong association between elevated levels of p-tau217 and future instances of mild cognitive impairment and dementia.

Women with higher levels of p-tau217 at the beginning of the study were significantly more likely to develop dementia later on. The findings were published in JAMA Network Open, highlighting the potential for early detection of dementia risk through a simple blood test.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, the study’s first author and an associate professor of public health and medicine at UC San Diego. “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”

This early detection could pave the way for preventive strategies and targeted monitoring, allowing for interventions before memory issues disrupt daily life. Shadyab emphasized that as research progresses, these biomarkers could help pinpoint individuals at the greatest risk and inform strategies to delay or prevent dementia.

However, the relationship between p-tau217 levels and dementia risk was not uniform across all demographics. The study indicated that women over 70 with elevated p-tau217 levels experienced poorer cognitive outcomes compared to their younger counterparts. Additionally, those with the APOE ε4 gene, a known risk factor for Alzheimer’s disease, also showed a stronger correlation between p-tau217 levels and cognitive decline.

Interestingly, the study revealed that p-tau217 was a more significant predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy, compared to those who received a placebo. This finding suggests that hormonal factors may play a role in the relationship between p-tau217 levels and dementia risk.

Senior author Linda K. McEvoy, a senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, noted the advantages of blood-based biomarkers like p-tau217. “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” she explained. “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Despite the promising nature of these findings, Shadyab cautioned that blood tests for Alzheimer’s disease are still under investigation and are not yet recommended for routine screening in asymptomatic individuals. Further research is necessary before this approach can be considered for clinical use prior to the onset of cognitive symptoms.

Future studies should explore how various factors, including genetics, hormone therapy, and age-related medical conditions, may interact with plasma p-tau217 levels. Shadyab also pointed out that the study focused exclusively on older women, indicating that the findings may not be applicable to men or younger populations. Additionally, the research examined overall dementia outcomes rather than specific subtypes, such as Alzheimer’s disease.

As the understanding of dementia risk factors evolves, the potential for early detection through blood tests like p-tau217 may revolutionize the approach to managing and preventing this debilitating condition.

According to Fox News Digital, the implications of this research could significantly impact future dementia prevention strategies.

Compounds in cannabis, particularly cannabidiol (CBD) and cannabigerol (CBG), may offer new treatment options for metabolic dysfunction-associated steatotic liver disease, a common chronic liver condition affecting many adults worldwide.

Research from the Hebrew University of Jerusalem suggests that compounds found in cannabis could pave the way for innovative treatments for the world’s most prevalent chronic liver disorder. The study, published in the British Journal of Pharmacology, highlights the potential of cannabidiol (CBD) and cannabigerol (CBG) in reducing liver fat and enhancing metabolic health in experimental models.

CBD is the more extensively researched non-intoxicating cannabinoid, while CBG serves as a precursor cannabinoid from which CBD is derived. Unlike THC, the primary psychoactive component of cannabis, both CBD and CBG do not induce a “high,” making them promising candidates for long-term medical applications.

Metabolic dysfunction-associated steatotic liver disease (MASLD) currently impacts approximately one-third of the global adult population, as indicated by health data. This condition is closely associated with obesity and insulin resistance, yet there are few approved pharmaceutical treatments available. Consequently, patients often rely on challenging lifestyle changes to manage their condition.

Lead study author Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, stated, “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function.”

The research emphasizes a process known as “metabolic remodeling,” where the cannabis compounds create a “backup battery” for the liver by increasing levels of phosphocreatine, a high-energy molecule stored in muscle cells. This energy reserve enables the liver to function more effectively under the stress of a high-fat diet, an unexpected finding noted by the research team.

Additionally, the study revealed that CBD and CBG restored the activity of “cellular cleaning crews,” known as cathepsins. These enzymes operate within the cell’s recycling centers to break down harmful fats and waste. As a result, the liver became more adept at clearing dangerous lipids, including triglycerides and ceramides, which are known to cause inflammation.

While both CBD and CBG demonstrated effectiveness, CBG yielded more pronounced results in specific areas, such as reducing total body fat mass, lowering “bad” LDL cholesterol, and improving insulin sensitivity. The researchers believe this study opens new avenues for utilizing plant-based compounds to treat metabolic diseases by focusing on cellular energy management and waste disposal.

Despite these promising findings, the research team cautioned that the study was conducted in a controlled experimental setting. Further clinical trials are essential to ascertain the appropriate application of these compounds for human patients.

Recent studies have also raised concerns regarding the use of cannabis as a medical treatment. A major analysis published in JAMA examined over 2,500 scientific papers from the past 15 years, including reviews, clinical trials, and guidelines related to medical marijuana. This review underscored significant discrepancies between public perception and scientific evidence regarding the effectiveness of cannabis for various medical conditions.

The researchers concluded that only a limited number of conditions have clear, well-established benefits from cannabinoid therapies supported by high-quality clinical data. “Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” noted Dr. Alex Dimitriu, who is double board-certified in psychiatry and sleep medicine. He emphasized that this study illustrates the reality that cannabis is not a universal remedy.

The strongest evidence currently supports FDA-approved cannabinoid medications for treating specific conditions, including appetite loss related to HIV/AIDS, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders.

Individuals interested in exploring marijuana for medical purposes are encouraged to consult with a healthcare provider to discuss potential risks and benefits, ensuring informed decision-making regarding their health.

According to Fox News, the implications of this research could significantly impact the future treatment landscape for liver diseases.

Recent studies indicate that GLP-1 drugs, including Ozempic and Wegovy, may increase fracture risk and osteoporosis in older adults with Type 2 diabetes, prompting calls for closer monitoring of bone health.

A new study suggests that GLP-1 medications, such as Ozempic and Wegovy, may elevate the risk of fractures by 11% in adults aged 65 and older who have Type 2 diabetes, compared to those using other diabetes treatments.

These GLP-1 drugs have revolutionized the management of Type 2 diabetes and obesity, but recent findings indicate that healthcare providers should be more vigilant regarding bone health in older patients prescribed these medications. A study published in February in the Journal of Clinical Endocrinology & Metabolism revealed that older adults with Type 2 diabetes who began using GLP-1 medications experienced a statistically significant increase in the risk of fragility fractures.

Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel and the study’s lead author, emphasized that while an 11% increase may seem modest, it is significant for a vulnerable population. “Both older age and Type 2 diabetes are independent risk factors for fragility fractures,” she stated. “This is a population that deserves special attention.”

Fragility fractures are typically caused by minor falls or routine activities and are often associated with osteoporosis. Such fractures can lead to hospitalization, loss of independence, and even increased mortality among older adults, according to Dr. Kasher Meron.

The study monitored over 46,000 adults aged 65 and older for nearly three years. After making necessary adjustments, researchers found that those using GLP-1 medications had a modest but statistically significant increase in fracture risk.

Previous studies involving younger patients using older GLP-1 medications did not indicate an increased fracture risk. However, the newer and more potent versions are now commonly prescribed to older adults, which alters the risk landscape. “In older adults treated with contemporary medications, the fracture risk picture looks different and warrants close attention,” Dr. Kasher Meron noted.

It is important to highlight that the study was observational, indicating an association rather than causation. Researchers could not ascertain whether the increased risk was due to weight loss, dietary changes, muscle loss, or a direct effect on bone health.

Despite these findings, Dr. Kasher Meron advocates for assessing bone health before initiating GLP-1 medications in older patients rather than treating it as an afterthought. The study’s results coincide with additional research presented at the American Academy of Orthopaedic Surgeons’ annual meeting, which raised further concerns regarding bone health.

In an analysis of over 146,000 adults with obesity and Type 2 diabetes, those using GLP-1 medications were found to have a 29% higher relative risk of developing osteoporosis over five years compared to nonusers. Additionally, rates of gout were slightly elevated, affecting 7.4% of GLP-1 users versus 6.6% of nonusers, representing a 12% relative increase. Osteomalacia, a condition characterized by softening of the bones, was rare but occurred approximately twice as often in GLP-1 users, according to the study, which has not yet undergone peer review.

Experts suggest several mechanisms may contribute to these findings. GLP-1 medications suppress appetite and can lead to rapid weight loss, which is known to reduce bone density. This reduction occurs partly because less mechanical load is placed on the skeleton. Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, likened this phenomenon to astronauts experiencing low bone density after extended periods in a zero-gravity environment.

Moreover, a decrease in caloric intake may result in lower consumption of calcium, vitamin D, and protein—nutrients essential for maintaining bone strength. Rapid weight loss can also temporarily elevate uric acid levels, a byproduct of tissue breakdown, potentially explaining the rise in gout cases.

Despite these concerns, experts caution against discouraging the appropriate use of GLP-1 medications, which have demonstrated significant benefits for blood sugar control, weight loss, and cardiovascular risk reduction. In addition to bone density screenings, experts recommend that patients ensure adequate nutrition and engage in resistance training to help preserve muscle and bone during weight loss.

A spokesperson for Novo Nordisk, the manufacturer of GLP-1 medications, stated that the company prioritizes patient safety and collaborates closely with the U.S. Food and Drug Administration (FDA). Liz Skrbkova, head of U.S. media relations for Novo Nordisk, emphasized that the known risks and benefits of these drugs are reflected in the current FDA-approved labeling. She noted that semaglutide, one of the GLP-1 medications, has shown cardiovascular, kidney, and liver benefits when used under medical supervision.

“Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova added.

These findings underscore the need for healthcare providers to closely monitor bone health in older adults prescribed GLP-1 medications, ensuring that the benefits of these treatments are balanced with potential risks.

According to Fox News Digital, the implications of these studies are significant for the management of diabetes and obesity in older populations.

New research suggests that GLP-1 weight-loss drugs may significantly reduce complications after heart attacks by improving blood flow to heart tissue.

Groundbreaking research indicates that a popular class of weight-loss drugs could play a crucial role in preventing life-threatening heart complications by reopening blocked blood vessels following heart attacks. The study, published this week in Nature Communications, was conducted by researchers from the University of Bristol and University College London.

The research identifies a biological signaling pathway involving the brain, gut, and heart, which may explain how GLP-1 drugs—medications that mimic the hormone glucagon-like peptide-1—help protect heart tissue from a condition known as “no-reflow.” This condition occurs when tiny blood vessels within the heart muscle remain constricted even after the main artery has been cleared during emergency treatment.

Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, highlighted the significance of the findings. “In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” she stated in a press release. “This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.” The lack of blood flow can increase the risk of heart failure and death within a year, but GLP-1 medications may offer a preventive solution.

The study reveals that when the GLP-1 hormone is released in the gut or administered as a medication, it sends signals to the brain. The brain, in turn, signals the heart to activate specific potassium channels in tiny cells known as pericytes. When these channels open, the pericytes relax, allowing small blood vessels, or capillaries, to widen and improve blood flow to the heart muscle.

Using animal models and cellular imaging, the researchers tracked how GLP-1 interacts with heart tissue. They discovered that when potassium channels were removed, the protective effects of the drugs on the heart were lost, confirming the channels’ critical role in this process.

The findings suggest that existing GLP-1 medications, which are already prescribed for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to minimize tissue damage.

However, the researchers acknowledged several limitations in their study, including its reliance on animal models. Clinical trials will be necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Moreover, while the study emphasizes the drug’s immediate benefits during a heart attack, it does not clarify whether long-term use of the medication provides any pre-existing level of protection.

This research was primarily funded by the British Heart Foundation, underscoring the potential implications for future heart attack treatments.

According to Fox News, the study opens new avenues for understanding how existing medications can be utilized to enhance heart health and reduce complications following cardiac events.

Researchers have discovered that levetiracetam, a decades-old seizure medication, may prevent the progression of Alzheimer’s disease if administered years before symptoms manifest.

A promising breakthrough in Alzheimer’s prevention has emerged from a recent study suggesting that levetiracetam, a medication traditionally used to treat seizures, may help halt the disease’s progression. Originally approved by the FDA in November 1999 under the brand name Keppra, levetiracetam is primarily prescribed for partial-onset seizures in adults, with its use later expanding to include children and various seizure types.

Researchers at Northwestern University have found that levetiracetam can prevent the formation of toxic amyloid beta peptides, which are small protein fragments commonly associated with Alzheimer’s disease. The study, published in Science Translational Medicine, revealed that the medication effectively inhibited the formation of amyloid-beta 42 in both animal models and cultured human neurons. This effect was also observed in post-mortem brain tissue from individuals with Down syndrome, a group at heightened risk for developing Alzheimer’s.

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid-beta 42 peptides and amyloid plaques,” said Jeffrey Savas, the study’s corresponding author and an associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine. “Our new results uncovered new biology while also opening doors for new drug targets.”

Savas explained that the brain is better equipped to avoid the pathways that produce toxic amyloid-beta 42 proteins during younger years. However, as individuals age, this ability diminishes. “This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he noted. This accumulation can lead to the formation of tau tangles—abnormal clumps of protein inside brain neurons—which can ultimately kill brain cells, trigger neuroinflammation, and result in dementia.

For levetiracetam to serve as an effective Alzheimer’s preventive, high-risk individuals would need to begin treatment “very, very early,” potentially up to 20 years before elevated levels of amyloid-beta 42 are detected. “You couldn’t take this when you already have dementia because the brain has already undergone a number of irreversible changes and a lot of cell death,” Savas cautioned.

The research team also analyzed existing clinical data to assess whether Alzheimer’s patients taking levetiracetam experienced a slower cognitive decline. They found that these patients had a “significant delay” in the time from cognitive decline to death compared to those not on the medication. “Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas stated.

Looking ahead, the research team aims to recruit individuals with genetic forms of Alzheimer’s for further testing. However, the study does have limitations, including its reliance on animal models and cultured cells, with no human trials conducted to date. As the study was observational, it cannot definitively prove that levetiracetam caused the prevention of toxic brain proteins.

Savas acknowledged that while levetiracetam shows promise, it is not without its drawbacks. The medication breaks down in the body relatively quickly, prompting the research team to work on developing a “better version” that would have a longer duration of action and more effectively target the mechanism responsible for preventing plaque production.

Common side effects of levetiracetam include drowsiness, weakness, dizziness, irritability, headache, loss of appetite, and nasal congestion. The medication has also been associated with potential mood and behavior changes, such as anxiety, depression, agitation, and aggression. In rare cases, it may lead to severe allergic reactions, skin reactions, blood disorders, and suicidal ideation.

Funding for this study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund. For further details, Fox News Digital reached out to both the drug manufacturer and the researchers for additional comments.

Experts caution individuals with diabetes to be vigilant about certain supplements that may adversely affect blood sugar levels and interact with medications.

Health experts are urging individuals with diabetes to exercise caution when considering dietary supplements, as some may pose significant risks by affecting blood sugar levels or interacting negatively with prescribed medications.

Surveys indicate that approximately 75% of U.S. adults have used dietary supplements, with 58% reporting usage within the past 30 days. However, experts emphasize that certain groups, particularly those with diabetes, should be particularly careful.

Dietary supplements encompass a wide range of products, including vitamins, minerals, herbs, amino acids, and probiotics, all designed to fill nutritional gaps and promote overall wellness. Some supplements target specific health functions, such as immune support, muscle recovery, and bone health.

Unlike prescription medications and over-the-counter drugs, dietary supplements are not typically approved by the Food and Drug Administration (FDA) before they hit the market. However, the FDA does regulate these products and can take action against those deemed unsafe or misbranded.

According to the National Institutes of Health (NIH), several supplements may pose serious health risks for individuals with diabetes. Dawn Menning, a registered dietitian and certified diabetes care and education specialist based in California, highlights St. John’s Wort as a supplement to avoid. While it is often marketed as a natural remedy for mild to moderate depression, it can interfere with diabetes medications by altering how the body metabolizes them.

“This can make medications less effective and complicate blood sugar management,” Menning explained. Although some claim that St. John’s Wort can help regulate blood sugar in individuals with type 2 diabetes, the evidence supporting this is limited and mixed.

Menning warns that combining this supplement with insulin or oral diabetes medications may increase the risk of hypoglycemia, a condition characterized by dangerously low blood sugar levels that can lead to dizziness, fatigue, and fainting.

Another supplement of concern is high-dose niacin, which is sometimes used to manage cholesterol levels. However, Menning cautions that it can significantly raise blood sugar levels, making it difficult to maintain an optimal A1c range.

Asian ginseng is often associated with increased energy, focus, and immune health. While it may offer some benefits for individuals with prediabetes and diabetes, there is evidence suggesting that it could lower blood sugar levels when taken alongside diabetes medications.

Jordan Hill, a registered dietitian with Top Nutrition Coaching in Colorado, advises against β-carotene supplementation for people with diabetes. The American Diabetes Association has linked this supplement to increased risks of lung cancer and cardiovascular mortality.

Cinnamon, frequently promoted for diabetes management and weight loss, has shown potential in reducing blood sugar and lowering insulin resistance. However, excessive consumption can lead to hypoglycemia, as well as liver damage due to a compound called coumarin found in cinnamon.

Oral aloe vera is another supplement that has gained popularity for its purported benefits for diabetes and weight loss. However, when combined with diabetes medications, it may cause blood sugar levels to drop too low, increasing the risk of hypoglycemia. Gastrointestinal side effects are also a concern with aloe vera.

Menning notes that for most supplements, there is insufficient evidence to support any beneficial effects on diabetes or its complications. The American Diabetes Standards of Care state that “without underlying deficiency, there are no benefits from herbal or nonherbal (i.e., vitamin or mineral) supplementation for people with diabetes.”

Furthermore, the American Association of Clinical Endocrinology advises caution with all unregulated nutritional supplements due to their inconsistent composition, quality, and potential for harm.

Experts recommend consulting with a healthcare provider before starting any supplement regimen to better understand how it may impact blood sugar levels, medications, or overall diabetes management.

For more information on the risks associated with dietary supplements for people with diabetes, refer to the National Institutes of Health.

A newly discovered virus within gut bacteria may be linked to an increased risk of colorectal cancer, offering new insights into the disease’s development, according to recent research.

Scientists in Denmark have identified a previously unknown virus residing in the gut bacterium Bacteroides fragilis, which may be associated with the development of colorectal cancer. The study, published in *Communications Medicine* earlier this month, reveals that patients diagnosed with colorectal cancer are approximately twice as likely to carry this virus compared to individuals without the disease.

Dr. Flemming Damgaard, PhD, from the Department of Clinical Microbiology at Odense University Hospital and the University of Southern Denmark, emphasized the significance of microorganisms in relation to human health. “These findings highlight the importance of the microorganisms in the gut and their relation to our health,” he stated. “If we want to understand the full picture, we need to look deep into their genetic material.”

For years, medical professionals have noted a higher prevalence of Bacteroides fragilis in colorectal cancer patients. However, since this bacterium is also commonly found in healthy individuals, the reasons for its harmful effects in certain cases remained unclear. This prompted researchers to investigate subtle genetic variations within the bacteria, leading to an unexpected discovery.

“We were very surprised to find a whole virus inside the bacteria from the colorectal cancer patients,” Damgaard remarked. “That was not something we expected when we started our study.”

The identified virus, classified as a bacteriophage, specifically infects bacteria rather than human cells. Notably, this viral type had not been documented prior to this research. The study involved analyzing stool samples from 877 individuals across Europe, the United States, and Asia, revealing that colorectal cancer patients were about twice as likely to carry traces of the virus compared to their cancer-free counterparts.

While the findings indicate a strong statistical association, researchers caution that the study does not establish a causal link between the virus and colorectal cancer. “The major limitation is that we still don’t know why the virus is linked to colorectal cancer,” co-author Ulrik Stenz Justesen explained. “But we are already continuing our research.”

The research team is currently conducting laboratory experiments and animal studies to explore whether the virus influences the behavior of Bacteroides fragilis in a manner that could contribute to cancer development.

Studies have shown that the human body is home to roughly as many microbial cells as human cells, highlighting the intricate relationship between microbes and overall health. “Our understanding of [microbial cells] is still in its infancy,” Damgaard noted. “There are many health-related discoveries to be made in the human microbiota.”

Colorectal cancer ranks among the leading causes of cancer-related deaths globally, according to the World Health Organization. The disease has gained increased visibility due to the deaths of several high-profile individuals, including James Van Der Beek, Catherine O’Hara, Kirstie Alley, Pelé, and Chadwick Boseman, underscoring its impact across various age groups.

While diet and lifestyle factors are significant contributors to colorectal cancer risk, researchers believe that gut bacteria may also play a crucial role. Current screening methods for colorectal cancer include stool tests that detect hidden blood and colonoscopies. In the future, researchers suggest it may be possible to test stool samples for viral markers similar to those identified in this study.

The researchers pointed to cervical cancer as an example of how recognizing a viral cause can enhance prevention efforts. Following the link between HPV and cervical cancer, vaccination programs have significantly reduced new cases. Although it is premature to draw direct comparisons, the researchers remain hopeful that colorectal cancer could follow a similar trajectory if a definitive viral role is established.

“It is too early to act,” Damgaard cautioned. “We have a lot of hope, and that is what we want people to have at this point,” he concluded.

According to Fox News Digital, this research opens new avenues for understanding the complexities of colorectal cancer and the potential role of viruses within the gut microbiome.

James Van Der Beek’s death underscores a troubling rise in colon cancer cases among younger adults, prompting urgent calls for increased awareness and earlier screening.

Following the death of actor James Van Der Beek after a two-and-a-half-year battle with colon cancer, health experts are sounding the alarm about the increasing prevalence of this disease among younger individuals. The star of “Dawson’s Creek” publicly shared his stage 3 colon cancer diagnosis in November 2024, although he was officially diagnosed in August 2023 after undergoing a colonoscopy.

In an August 2025 interview with Healthline, Van Der Beek revealed that the first warning sign of his colon cancer was a change in his bowel movements, which he initially attributed to his coffee consumption. “Before my diagnosis, I didn’t know much about colorectal cancer,” he admitted. “I didn’t even realize the screening age had dropped to 45; I thought it was still 50.”

Recent research has highlighted a concerning trend: colorectal cancer (CRC) has become the leading cause of cancer-related death among men and women aged 50 and younger, according to the American Cancer Society. This marks a significant shift from the 1990s, when CRC was the fifth deadliest cancer in this age group. While overall cancer deaths have declined by approximately 44% since 1990, CRC is the only major cancer that has seen an increase in mortality rates for those under 50 during this time.

Dr. Aparna Parikh, medical director of the Center for Young Adult Colorectal Cancer at the Mass General Cancer Center, noted that the reasons behind this rise remain unclear. “Experts don’t entirely understand why cases are on the rise,” she explained. “But it seems to be an interplay of a person’s risk factors, overall makeup, and early exposures.” These exposures may include dietary habits, environmental factors, and even antibiotic use, along with lifestyle choices.

A recent study by the American Cancer Society found that long-term heavy drinking is associated with an increased risk of developing colorectal cancer. Other significant risk factors include family history of the disease, obesity, smoking, a diet high in red and processed meats, inflammatory bowel disease, and a personal or family history of polyps.

In a recent appearance on “America’s Newsroom,” Fox News senior medical analyst Dr. Marc Siegel discussed the rising incidence of CRC among younger adults. He highlighted the role of genetics and the consumption of ultraprocessed foods, citing a study from Mass General that indicates a diet high in such foods increases the likelihood of colon cancer by 45%. Additionally, a diet rich in processed meats, such as hot dogs, raises the risk by 30%, while a diet high in red meat increases the risk by 20%.

Experts emphasize that while colorectal cancer may not present symptoms in its early stages, certain signs should not be ignored. Dr. Eitan Friedman, Ph.D., an oncologist and founder of The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center in Israel, confirmed that changes in bowel habits are a primary red flag for colorectal cancer. Other symptoms include fatigue due to anemia, abdominal pain or discomfort, rectal bleeding, weakness, and unexplained weight loss.

Dr. Erica Barnell, Ph.D., a physician-scientist at Washington University School of Medicine and co-founder of Geneoscopy, noted that Van Der Beek’s experience of having no obvious symptoms is not uncommon. “Many colorectal cancers develop silently, without obvious symptoms,” she explained. “By the time symptoms appear, the disease may already be advanced.”

Early detection is crucial for improving outcomes in colorectal cancer cases. “Colonoscopy at age 45 onwards, at five- to ten-year intervals, has been shown to lead to early detection of polyps that have the potential to become malignant,” Dr. Friedman stated. “Removing these polyps can significantly minimize the risk of malignant transformation.”

Unfortunately, Dr. Barnell pointed out that screening compliance in the United States remains below national targets, with the most significant gaps found in rural, low-income, and minority communities. “Most people don’t like talking about bowel habits, but paying attention to changes can save your life,” she urged. “Screening gives us the chance to find problems early—often before you feel sick—and that can make all the difference.”

Dr. Siegel reiterated the importance of colonoscopies as the most effective method for screening CRC, especially when polyps are detected and removed before they can develop into cancer. The rising incidence of colorectal cancer among younger adults, as exemplified by Van Der Beek’s tragic story, serves as a stark reminder of the need for increased awareness and proactive health measures.

As the conversation around colorectal cancer continues to evolve, it is essential for individuals to stay informed about their health and the importance of early screening. According to the American Cancer Society, understanding risk factors and recognizing warning signs can be life-saving.

James Van Der Beek highlighted a critical warning sign of colorectal cancer months before his passing, emphasizing the importance of early screening at age 45.

James Van Der Beek, the actor best known for his role in “Dawson’s Creek,” shared an important warning sign of his stage 3 colon cancer prior to his death at the age of 48. His wife, Kimberly Van Der Beek, confirmed his passing in a heartfelt social media post on Wednesday.

In November 2024, Van Der Beek received a diagnosis of colorectal cancer, but he had previously expressed to Healthline in August that he had not experienced any alarming symptoms. “There wasn’t any red flag or something glaring,” he stated. Despite maintaining a healthy lifestyle, including cold plunges and excellent cardiovascular fitness, he was unaware of his cancer diagnosis.

The only symptom he did notice was a change in his bowel movements, which he initially attributed to his coffee consumption. “Before my diagnosis, I didn’t know much about colorectal cancer,” Van Der Beek admitted. He was surprised to learn that the recommended screening age had been lowered to 45, believing it was still set at 50.

Ultimately, a colonoscopy revealed that he had stage 3 colon cancer. Professor Eitan Friedman, M.D., Ph.D., an oncologist at the Sheba Medical Center in Israel, confirmed that changes in bowel habits are a primary indicator that should raise suspicion for colorectal cancer. Other symptoms can include fatigue linked to anemia, blood in the stool, weight loss, loss of appetite, and abdominal discomfort.

Dr. Erica Barnell, M.D., Ph.D., a physician-scientist at Washington University School of Medicine and co-founder of Geneoscopy, noted that Van Der Beek’s experience of having no obvious symptoms is not uncommon. “Many colorectal cancers develop silently, without obvious symptoms,” she explained. “By the time symptoms appear, the disease may already be advanced.”

Friedman highlighted that symptoms are particularly concerning for individuals aged 45 and older who have at least one first-degree relative with colon cancer or other gastrointestinal malignancies, as well as those with active inflammatory bowel diseases like ulcerative colitis or Crohn’s disease.

The lifetime risk of developing colorectal cancer for an average-risk individual is estimated to be between 4% and 5%. Friedman emphasized the importance of colonoscopies starting at age 45, recommending them every five to ten years. This approach has been shown to facilitate early detection of polyps that could become malignant, allowing for their removal and significantly reducing the risk of cancer.

Despite the clear benefits of screening, Barnell pointed out that compliance in the U.S. remains below national targets, with the largest gaps found in rural, low-income, and minority communities. To address these disparities, she advocates for improved access to accurate, noninvasive screening technologies and increased public awareness.

“Most people don’t like talking about bowel habits, but paying attention to changes can save your life,” Barnell stressed. “Screening gives us the chance to find problems early — often before you feel sick — and that can make all the difference.”

For more health-related articles, visit www.foxnews.com/health. Fox News Digital previously reached out to Van Der Beek’s representative for comment.

Men are at a significantly higher risk of heart attacks than women, with the threat emerging as early as their mid-30s, according to a new study from Northwestern University.

A recent study conducted by researchers at Northwestern University reveals that men face the risk of heart attacks seven years earlier than women, beginning in their mid-30s. This finding underscores the necessity for earlier cardiovascular screening for men.

The study, published in the Journal of the American Heart Association (JAHA), analyzed data from over 5,000 adults aged 18 to 30, collected from the mid-1980s through 2020. This research was part of the Coronary Artery Risk Development in Young Adults (CARDIA) study.

According to the findings, men reached a 5% incidence of cardiovascular disease—including heart attacks, strokes, and heart failure—around the age of 50, while women did not reach this threshold until approximately age 57. The primary contributor to this disparity was coronary heart disease, which occurs when the blood vessels supplying the heart muscle become narrowed or blocked. Notably, men experienced a 2% incidence of this condition more than a decade earlier than women. In contrast, the risks associated with stroke and heart failure appeared later in life.

The study indicates that men’s risk of developing heart disease begins to rise significantly around age 35 and remains elevated throughout midlife. All participants in the study were under 65 years old at the time of the last follow-up. Current guidelines typically recommend cardiovascular risk assessments starting at age 40, a practice some experts argue may overlook a critical window for early prevention.

Heart disease develops over many years, with early indicators becoming detectable in young adulthood. Senior study author Alexa Freedman, an assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine, emphasized the importance of promoting heart health screenings and preventive measures in young adulthood, particularly for young men.

Freedman stated, “Our findings highlight the importance of promoting heart health screening and prevention in young adulthood, especially for young men.” The researchers advocate for a more comprehensive approach to assessing heart risk, suggesting that it should extend beyond standard measures such as cholesterol and blood pressure to include a wider range of biological and social factors.

Dr. Andrew Freeman, a cardiologist and director of clinical cardiology at National Jewish Health in Denver, commented on the study’s findings, noting that it aligns with existing knowledge that men tend to experience heart attacks and strokes earlier than women. Although the study did not pinpoint the reasons for this predisposition, Freeman suggested that hormonal differences, dietary habits, and levels of physical activity could all contribute.

“The standard American lifestyle makes us all sick, and men seem to be more prone to developing this disease earlier,” Freeman remarked. He further noted that modern exposures to environmental toxins, such as those found in the food supply, as well as air, light, and sound pollution, are associated with an increased risk of heart disease.

Freeman also highlighted that lifestyle factors such as increased sedentary behavior, inadequate sleep, heightened stress levels, and reduced social connections can exacerbate cardiovascular issues. “I think this study is really underscoring that it’s time for some big changes,” he said.

To mitigate heart health risks, Freeman recommends addressing any existing comorbidities, such as high blood pressure, high cholesterol, and obesity. He suggests that individuals at higher risk for cardiovascular events may benefit from earlier screening, although he believes that early preventive measures should be applied universally.

“Coronary disease is manifesting earlier than ever here in the U.S., and we need to do everything we can to clean up our lifestyles and reduce our disease burden,” Freeman concluded. “If you’re a man, you’ve got to be extra aggressive earlier in life.”

These findings highlight the critical need for awareness and proactive measures in heart health, particularly among young men, to combat the rising incidence of cardiovascular disease.

According to Fox News, the study serves as a call to action for both individuals and healthcare providers to prioritize heart health from a younger age.

New research indicates that individuals who identify as “night owls” may face increased risks of heart attack and stroke due to circadian misalignment affecting their cardiovascular health.

Recent findings published in the Journal of the American Heart Association reveal that adults who consider themselves “evening people” tend to have poorer cardiovascular health and a higher risk of heart-related issues. The study examined the relationship between a person’s chronotype—whether they are naturally inclined to be active in the morning or evening—and their overall heart health.

The research analyzed 14 years of data from the UK Biobank, involving approximately 300,000 adults with an average age of 57. According to the study, around 8% of participants identified as “definitely evening people,” meaning they typically stayed up very late. In contrast, 24% classified themselves as “definitely morning people,” who tended to rise and retire early. The remaining 67% fell into an “intermediate” category, expressing uncertainty about their chronotype.

Heart health was assessed using the American Heart Association’s Life’s Essential 8 score, which evaluates various factors including activity levels, diet, blood pressure, cholesterol, nicotine use, sleep patterns, weight management, and blood sugar levels. Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution, explained the significance of this comprehensive assessment.

The researchers also tracked the incidence of heart attacks and strokes during the follow-up period. They found that individuals who were more active in the evening exhibited a 79% higher risk of poor cardiovascular health compared to those in the intermediate group. Additionally, they faced a 16% increased risk of heart attack or stroke. Conversely, those who identified as morning people had slightly better heart health scores, with the effects being more pronounced in women than in men.

Lead study author Sina Kianersi, Ph.D., a research fellow at Brigham and Women’s Hospital and Harvard Medical School, noted that “evening people” often experience circadian misalignment. This misalignment occurs when their internal body clock does not synchronize with the natural light-dark cycle or their daily routines. Kianersi pointed out that evening people may engage in behaviors detrimental to cardiovascular health, such as poor diet, smoking, and irregular sleep patterns.

Dr. Serwer, who was not involved in the study, emphasized the role of lifestyle habits in these findings. “Cardiovascular disease has multiple contributing causes,” he stated. “Sleep is just one variable—and the importance of high-quality, restorative sleep should not be undervalued.” The implications of these findings could guide healthcare providers in developing tailored lifestyle and medical interventions aimed at preventing cardiovascular events.

However, the study does have limitations. It does not establish a causal relationship between staying up late and heart problems but rather indicates an association. Additionally, the research relied on self-reported data regarding schedules, habits, and health, which may introduce bias. The UK Biobank participants are primarily White and generally healthier than the average population, suggesting that the results may not be broadly applicable.

Dr. Serwer added that while quality sleep is crucial, further research is necessary to determine the specific impact of sleep on cardiovascular health.

These findings highlight the importance of understanding how sleep patterns can influence heart health and underscore the need for continued investigation into the relationship between lifestyle choices and cardiovascular outcomes, according to Fox News Digital.

Ritesh Shah, founder of the Ritesh Shah Charitable Pharmacy, has been recognized in the ’50 Most Influential People in Pharmacy’ list for his impactful work in equitable healthcare.

RED BANK, NJ – Healthcare innovator Ritesh Shah has been named one of the ’50 Most Influential People in Pharmacy,’ a prestigious national ranking that honors leaders for their advocacy and service within the pharmacy profession.

Shah is the founder of the Ritesh Shah Charitable Pharmacy, a nonprofit organization dedicated to providing essential medications at no cost to uninsured and underinsured individuals. His work as a community pharmacist has garnered attention for establishing a sustainable and scalable model for equitable healthcare delivery.

In response to his recognition, Shah expressed his gratitude, stating, “I’m deeply honored by this recognition. Pharmacy is ultimately about people—meeting patients where they are and ensuring access to life-saving medications. This work is only possible because of the dedicated partners, volunteers, and communities we serve.”

The ‘Pharmacy50’ ranking highlights professionals who are actively transforming the pharmaceutical landscape. Shah’s initiatives have concentrated on enhancing patient access, ensuring medication affordability, and supporting the long-term viability of independent pharmacies. His leadership has been pivotal in repositioning pharmacists as crucial frontline responders, thereby influencing national policy discussions toward more compassionate healthcare solutions.

Shah’s dedication to public health has redefined the role of independent pharmacies, establishing them as trusted community hubs. His nonprofit initiative is frequently referenced as a benchmark for how mission-driven healthcare can significantly improve patient outcomes on a broad scale.

According to India-West, Shah’s contributions to the field of pharmacy exemplify the impact of community-focused healthcare initiatives.

New research indicates that early introduction of peanuts to infants significantly reduces the risk of developing food allergies, with eggs now being the most common allergen among children.

Recent studies have shifted the longstanding advice regarding peanut consumption in infants, suggesting that early exposure can significantly lower the risk of developing food allergies. A study conducted by the Children’s Hospital of Philadelphia, published in October 2025 in the journal *Pediatrics*, found that introducing peanuts during infancy led to a 27% decrease in peanut allergy diagnoses and a 38% reduction in overall food allergies among children.

Historically, parents were advised to avoid giving peanuts to babies for the first few years of life. However, emerging research supports the idea that introducing peanuts as early as 4 to 11 months can help prevent allergies. This change in perspective stems from the landmark 2015 Learning Early About Peanut Allergy (LEAP) trial, which demonstrated that infants with severe eczema or an egg allergy could reduce their risk of developing a peanut allergy by 81% when exposed to peanuts early.

The updated guidelines from the National Institute of Allergy and Infectious Diseases in 2021 further encouraged parents to introduce peanuts, eggs, and other major food allergens as early as 4 to 6 months, even for children without prior allergic reactions. This shift aims to combat the rising prevalence of food allergies among children.

Dr. Stanislaw Gabryszewski, the first author of the study and an attending physician in the Division of Allergy and Immunology at the Children’s Hospital of Philadelphia, expressed optimism about the findings. “Everyone has been wondering whether these landmark public health interventions have had an impact on reducing rates of IgE-mediated food allergies in the United States,” he stated. “We now have data that suggest the effect of this landmark public health intervention is occurring.”

The study’s authors emphasized the importance of education and advocacy surrounding early food introduction practices. They noted that if these findings are confirmed, they would represent a significant advancement in public health, demonstrating that clinical research, when paired with clear guidelines, can effectively alter the trajectory of childhood food allergies.

While the study provides valuable insights, it is important to note that it only included data up to early 2019 and did not account for the 2021 guidelines promoting the early introduction of multiple allergens. Additionally, the research relied on electronic health records for allergy diagnoses, which may overlook some cases, and did not capture individual feeding patterns. As an observational study, it can only establish associations rather than direct cause-and-effect relationships.

Food allergies can pose serious health risks, with peanut allergies in particular leading to severe, life-threatening reactions such as difficulty breathing, throat swelling, and a dangerous drop in blood pressure. These reactions necessitate immediate treatment with epinephrine, a critical allergy medication.

Despite the encouraging findings, not all parents may feel comfortable adhering to the revised guidelines. Dr. Susan Schuval, chief of the Division of Pediatric Allergy and Immunology at Stony Brook Children’s Hospital, noted, “Not everyone has followed those guidelines, but this is further evidence that this early introduction is effective at preventing food allergies.” She encourages parents to consult with their pediatricians regarding any concerns before introducing potential food allergens to their children.

The evolving understanding of food allergies highlights the importance of ongoing research and communication between healthcare providers and families. As more data emerges, the hope is to further reduce the incidence of food allergies and improve the health outcomes for children.

According to Fox News Digital, the implications of these findings could lead to a broader acceptance of early allergen introduction, ultimately benefiting public health.

Viti Vitamins, co-founded by Dr. Pravesh Saini and Anshika Saini, aims to transform brain and nerve health by offering a proactive approach to chronic migraines through scientifically-backed nutrition.

In a wellness market saturated with generic supplements, Viti Vitamins is carving out a unique identity by addressing a widespread yet often misunderstood issue: chronic migraines and headaches. Founded by neurologist Dr. Pravesh Saini and product strategist Anshika Saini, this Los Angeles-based brand is built on the powerful idea of merging clinical precision with everyday simplicity to support brain and nerve health through consistent, proactive nutrition.

Rather than viewing migraines as mere inconveniences, Viti Vitamins treats them as chronic neurological conditions that require daily care rather than reactive solutions. This innovative perspective is at the core of the brand’s mission.

The inspiration for Viti Vitamins stemmed directly from Dr. Saini’s extensive experience in clinical neurology. After training at Loyola Stritch School of Medicine and completing a Neurology residency and Neurocritical Care subspecialization at the University of Southern California, Dr. Saini spent years treating patients whose lives were disrupted by frequent headaches and migraines.

Over time, he observed a recurring pattern among his patients. “Patients were looking for preventative care, but the market offered fragmented solutions,” Dr. Saini explained. “Most products focused on a single ingredient, like magnesium or B2, forcing people to piece together multiple supplements. It was expensive, confusing, and unsustainable.”

Despite clinical research consistently supporting the role of multiple nutrients in migraine prevention, over-the-counter options rarely reflected that science in a single, reliable product. This disconnect between clinical efficacy and commercial availability became the foundation for Viti Vitamins.

The brand’s debut product, Viti Vitamins Migraine Support Gummies, embodies its commitment to clinical integrity and daily usability. These gummies feature a first-of-its-kind blend of six nutrients commonly recommended by neurologists for migraine support: Magnesium, Vitamin B2, Vitamin B6, CoQ10, Feverfew, and Ginger.

Designed for consistent daily use, the formulation supports healthy nerve function over time rather than providing only temporary relief. Additionally, the product is intentionally clean—vegan, preservative-free, gelatin-free, and devoid of artificial dyes, fillers, sweeteners, and stimulants. Naturally colored with spirulina and sweetened, the gummies are crafted to encourage long-term adherence to the regimen.

Dr. Saini emphasized the importance of user experience, stating, “Our goal was to create something people could trust—and actually enjoy taking. If a product feels like a chore or causes side effects, people won’t stay consistent, no matter how effective it is on paper.”

While Dr. Saini leads the formulation and clinical direction, Anshika Saini oversees strategy, marketing, and brand development, ensuring that scientific rigor translates into an approachable consumer experience. With a background in product management and technology consulting at a Fortune 500 company, Anshika brings a systems-driven mindset to wellness innovation.

“When you’re managing a chronic condition, the last thing you need is a complicated, untrustworthy ritual,” she said. “We wanted to eliminate the guesswork and create a single-dose solution where science and simplicity align.”

For Anshika, Viti Vitamins represents an opportunity to empower individuals to regain control over their health without overwhelming them with jargon, excessive dosing schedules, or inconsistent formulations. Her vision focuses on developing holistic supplements that seamlessly integrate into everyday life, transforming evidence-based care into an effortless daily habit.

Together, Anshika and Dr. Saini exemplify a growing trend in health entrepreneurship: the fusion of medical expertise with consumer-first design. Their approach shifts migraine care from crisis management to long-term neurological wellness.

Rather than promising miracle cures, Viti Vitamins emphasizes integrity, consistency, and sustainability—principles the founders believe are essential for lasting vitality. “Brain and nerve health shouldn’t only be addressed when something goes wrong,” Anshika stated. “It should be supported every day, just like physical fitness or nutrition.”

As awareness around neurological wellness continues to rise, Viti Vitamins positions itself at the intersection of science-backed medicine and modern lifestyle design, offering a proactive solution for individuals seeking support rather than reactive relief.

From formulation to daily operations, the founders share a unified belief: lasting wellness is built through simple, trustworthy routines grounded in real science—not fleeting trends, according to Global Net News.

New research reveals that flu-positive individuals did not transmit the virus to healthy adults during a controlled study, suggesting key factors that may reduce flu transmission.

This year’s flu season has been characterized by an aggressive new strain, leading to record-high hospitalizations and severe symptoms across the United States. As public health officials seek ways to curb the spread of influenza, a groundbreaking study has uncovered several factors that may significantly reduce transmission rates.

Researchers from the University of Maryland Schools of Public Health and Engineering, alongside the School of Medicine in Baltimore, conducted a unique study on influenza transmission. They placed flu-positive college students in a hotel room with healthy middle-aged adult volunteers to observe potential virus spread.

The study, published in the journal PLOS Pathogens, is reportedly the first clinical trial to investigate how the flu spreads from naturally infected individuals to uninfected ones. A total of 11 healthy volunteers participated in the trial, living on a quarantined floor of a Baltimore-area hotel for two weeks. During this period, they engaged in various simulated interactions, including conversations, physical activities like yoga, and sharing objects such as pens and tablets.

Throughout the study, researchers closely monitored the participants for symptoms, conducted daily nasal swabs, and collected saliva and blood samples to test for antibodies. They also measured the “viral exposure” in the volunteers’ breathing air and the ambient air in the activity room. A specialized machine called the Gesundheit II, developed by Dr. Donald Milton and colleagues at Harvard T.H. Chan School of Public Health, was used to assess the exhaled breath of the participants.

At the conclusion of the experiment, none of the healthy individuals contracted the flu, a finding attributed to several factors. Notably, the infected students exhibited minimal coughing, which researchers noted was crucial since they were retaining “a lot of virus in their noses” and only releasing small amounts into the air.

Dr. Jianyu Lai, the study’s lead data analyst, emphasized that coughing is a significant factor in flu transmission. “Our data suggests key things that increase the likelihood of flu transmission — coughing is a major one,” he stated in a press release.

Another important factor identified was the ventilation and air movement within the study room. The air was continuously mixed by a heater and dehumidifier, which diluted the small amounts of virus present in the air. Lai pointed out that middle-aged adults typically exhibit lower susceptibility to influenza compared to younger adults.

Dr. Donald Milton, a professor at the University of Maryland’s Department of Global, Environmental and Occupational Health and an expert in infectious disease aerobiology, noted that most researchers assume airborne transmission is a primary mode of disease spread. “At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission,” he remarked. “What does this say about how flu spreads and how to stop outbreaks?”

Milton, who was among the first experts to identify effective measures to halt the spread of COVID-19, stressed the importance of findings from such trials in updating international infection-control guidelines. “Being up close, face-to-face with other people indoors where the air isn’t moving much, seems to be the most risky thing — and it’s something we all tend to do a lot,” he explained.

He further suggested that portable air purifiers, which can both stir up and clean the air, could be beneficial in reducing transmission risks. However, he cautioned that if individuals are in close proximity and someone is coughing, wearing a mask, particularly an N95, remains the best preventive measure.

According to data from the Centers for Disease Control and Prevention (CDC), approximately 11 million flu illnesses and around 5,000 deaths have been reported so far in the 2025-2026 influenza season. A significant portion of current flu cases is attributed to the new influenza A subclade K variant.

These findings could reshape our understanding of flu transmission and inform public health strategies aimed at mitigating outbreaks in the future, according to Source Name.

The first-ever fentanyl vaccine, designed to prevent overdoses, is set to enter human trials in early 2026 after successful animal studies.

A groundbreaking vaccine aimed at preventing fentanyl overdoses is on track for clinical trials in humans, following promising results from animal studies. This innovative vaccine is designed to block fentanyl from entering the brain, thereby preventing its lethal effects and reducing the risk of overdose. If successful, it would represent the first preventive treatment against fentanyl overdoses, which are a leading cause of drug-related fatalities in the United States.

Unlike existing treatments such as naloxone, which reverse the effects of an overdose after it occurs, this vaccine works proactively by creating antibodies that target fentanyl. The vaccine contains a synthetic fragment of fentanyl linked to a protein known as CRM197, along with an immune-activating compound called dmLT. This combination stimulates the immune system to produce antibodies that capture fentanyl in the bloodstream before it can reach the brain, according to Colin Haile, co-founder and scientific adviser of ARMR Sciences, the biotech company that licensed the vaccine.

“In a vaccinated individual, those anti-fentanyl antibodies are in the blood,” Haile explained. “If they consume fentanyl, the antibodies grab onto the drug and prevent it from getting into the brain. They would feel no effects if they ingest fentanyl — absolutely none. And they would not overdose.” He added that eventually, the fentanyl would be eliminated from the body.

In studies conducted on mice and rats, researchers observed that the animals maintained antibodies against fentanyl for up to six months after vaccination. While some critics have raised concerns that such a vaccine might inadvertently encourage drug use, Haile countered that vaccinated individuals would not experience the euphoric effects typically associated with fentanyl, thus diminishing the incentive for misuse. The primary advantage of the vaccine, he noted, is its potential to mitigate the health risks associated with fentanyl use, particularly respiratory depression, which is the leading cause of death from this potent synthetic opioid.

The initial human clinical trial is scheduled to begin in early 2026 at the Center for Human Drug Research, affiliated with the University of Leiden in the Netherlands. This small Phase 1 trial will enroll approximately 40 participants and will focus on assessing the vaccine’s safety and immune response. Following the Phase 1 trial, a Phase 2 trial will evaluate the vaccine’s effectiveness in blocking fentanyl’s effects in humans.

Currently, the data available is limited to animal models, and it remains uncertain how effective the vaccine will be in humans. However, Haile reported that no adverse side effects were observed in the animal studies, likely due to the fact that the vaccine’s components are proteins that have been previously used in other human applications, establishing a known safety profile. He emphasized that the doses used in the vaccine are extremely low, and even in toxicology studies where animals received doses 20 times higher than what would be administered to humans, no signs of toxicity were detected.

Haile identified several potential use cases for the vaccine, particularly for individuals with opioid use disorder who are seeking to quit using fentanyl. It could also serve as a protective measure for first responders and healthcare workers at risk of accidental exposure to fentanyl. Additionally, military and national security personnel could benefit from the vaccine, as it may offer protection against fentanyl and similar compounds that could be used as chemical threats. Parents of at-risk teens or young adults may also seek the vaccine, given the prevalence of fentanyl being mixed with other substances, such as marijuana.

Looking ahead, Haile expressed optimism that this vaccine could pave the way for the development of other anti-drug vaccines targeting substances like cocaine and methamphetamine, which are already in the pipeline. “If we can tackle the primary ones — fentanyl, cocaine, and methamphetamine — we will be saving hundreds of thousands of lives,” he stated.

Dr. Marc Siegel, senior medical analyst for Fox News, described the vaccine’s progress as a “very exciting advance with a huge upside.” He expressed enthusiasm about the upcoming human trials, noting that the vaccine could significantly reduce the number of overdoses resulting from fentanyl use. “This is likely to prevent many overdoses where a patient is sedated and stops breathing as a result of fentanyl,” Siegel remarked.

While the antidote for fentanyl, known as Narcan, is effective, it has limitations. Fentanyl can remain in the system for many hours, while Narcan, an opioid antagonist, wears off after a few hours and requires re-administration. Siegel cautioned that the vaccine should be targeted toward those truly at risk for opioid overdoses and addiction, as fentanyl also serves important medical purposes, such as pain management for cancer patients and use in anesthesia.

The development of this vaccine has been supported by funding from the U.S. Department of Defense and is licensed to ARMR Sciences, which is working to bring this innovative solution to market.

As the landscape of opioid use and addiction continues to evolve, the potential impact of this vaccine could be transformative, offering a new avenue for prevention and protection against one of the most dangerous substances in circulation today, according to Fox News.